{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T22:48:55Z","timestamp":1789858135642,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jbspin.2018.08.003","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T12:48:45Z","timestamp":1536324525000},"page":"343-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Safety of biological agents in paediatric rheumatic diseases: A real-life multicenter retrospective study using the JIRcohorte database"],"prefix":"10.1016","volume":"86","author":[{"given":"Natalia","family":"Cabrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Lega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrouz","family":"Kassai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuela","family":"Kondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Cannizzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Woerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Chausset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Roethlisberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Jeanneret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Aeschlimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Duquesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Higel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Berthet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Hentgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Kone-Paut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Belot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2018.08.003_bib0005","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bcp.12305","article-title":"Clinical trials in children","volume":"79","author":"Joseph","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0010","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0015","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0020","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0025","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.39145","article-title":"Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study","volume":"67","author":"Horneff","year":"2015","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0030","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0035","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0040","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0045","doi-asserted-by":"crossref","first-page":"R202","DOI":"10.1186\/ar3535","article-title":"Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study","volume":"13","author":"Kon\u00e9-Paut","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0050","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1177\/0961203310395802","article-title":"Assessment of flares in lupus patients enrolled in a phase II\/III study of rituximab (EXPLORER)","volume":"20","author":"Merrill","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0055","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0060","first-page":"S67","article-title":"Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort","volume":"33","author":"Anton","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0065","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/rheumatology\/keu457","article-title":"Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting","volume":"54","author":"Tarkiainen","year":"2015","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0070","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1136\/annrheumdis-2013-204641","article-title":"Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national arthritis and biologics in children register","volume":"74","author":"Otten","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0075","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/rheumatology\/kev416","article-title":"Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome","volume":"55","author":"Kuemmerle-Deschner","year":"2016","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0080","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","article-title":"Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab","volume":"18","author":"Horneff","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0085","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/0961203316662720","article-title":"Clinical characteristics of children with membranous lupus nephritis: the childhood arthritis and rheumatology research alliance legacy registry","volume":"26","author":"Boneparth","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0090","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.semarthrit.2016.07.001","article-title":"Biological agents in polyarticular juvenile idiopathic arthritis: A meta-analysis of randomized withdrawal trials","volume":"46","author":"Amarilyo","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0095","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/rheumatology\/kev382","article-title":"Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials","volume":"55","author":"Tarp","year":"2016","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0100","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/annrheumdis-annrheumdis-2014-206747","article-title":"Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA)","volume":"75","author":"Klotsche","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0105","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.34348","article-title":"Rates of malignancy associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0110","doi-asserted-by":"crossref","first-page":"e000212","DOI":"10.1136\/rmdopen-2015-000212","article-title":"Malignancy incidence in 5294 patients with juvenile arthritis","volume":"2","author":"Zahevi Niaki","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0115","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/ar4213","article-title":"What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?","volume":"15","author":"Swart","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0120","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/pds.3982","article-title":"Quality of serious adverse events reporting to academic sponsors of clinical trials: far from optimal","volume":"25","author":"Cr\u00e9pin","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0125","first-page":"390","article-title":"International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0130","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/ard.2003.014886","article-title":"The German etanercept registry for treatment of juvenile idiopathic arthritis","volume":"63","author":"Horneff","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0135","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.2007.087411","article-title":"Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register","volume":"68","author":"Prince","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10067-014-2744-6","article-title":"Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis","volume":"34","author":"Windschall","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0145","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/03009742.2010.517546","article-title":"Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis","volume":"40","author":"Trachana","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0150","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.38741","article-title":"Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German biologics JIA registry","volume":"66","author":"Schmeling","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0155","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"16","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0160","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/ard.2008.100008","article-title":"Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis","volume":"68","author":"Hoes","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0165","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","article-title":"Society for rheumatology biologics register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study","volume":"56","author":"Hyrich","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0170","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/ard.2007.075895","article-title":"Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis","volume":"67","author":"C\u00e9spedes-Cruz","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jbspin.2015.03.005","article-title":"Impact of juvenile idiopathic arthritis on quality of life during transition period at the era of biotherapies","volume":"83","author":"Wipff","year":"2016","journal-title":"J Bone Spine Rev Rhum"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0180","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/rheumatology\/kev398","article-title":"Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt","volume":"55","author":"Mour\u00e3o","year":"2016","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0185","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","article-title":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial","volume":"70","author":"Tynj\u00e4l\u00e4","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0190","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/art.34343","article-title":"Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis","volume":"64","author":"Wallace","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0195","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2014.212","article-title":"Management of juvenile idiopathic arthritis: hitting the target","volume":"11","author":"Hinze","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0200","doi-asserted-by":"crossref","first-page":"e20161209","DOI":"10.1542\/peds.2016-1209","article-title":"Infectious complications with the use of biologic response modifiers in infants and children","volume":"138","author":"Davies","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0205","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0210","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.2009.100354","article-title":"Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension","volume":"69","author":"Ruperto","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0215","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/ard.2007.087593","article-title":"Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA registry","volume":"68","author":"Horneff","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.08.003_bib0220","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jbspin.2015.06.004","article-title":"Managing monoarthritis in children","volume":"83","author":"Devauchelle-Pensec","year":"2016","journal-title":"J Bone Spine Rev Rhum"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X18302835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X18302835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:24:39Z","timestamp":1761150279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X18302835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1297319X18302835"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2018.08.003","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of biological agents in paediatric rheumatic diseases: A real-life multicenter retrospective study using the JIRcohorte database","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2018.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}